@article{178f0e4e2cdd4d54b8e7b91a2e584bf7,
title = "The Clinical Management of Clonal Hematopoiesis: Creation of a Clonal Hematopoiesis Clinic",
abstract = "The acquisition of mutations in hematologic stem cells (clonal hematopoiesis) is common with normal aging and can be identified as an incidental finding through clinical genetic testing. Clonal hematopoiesis is associated with a heightened risk of developing hematologic neoplasms (especially myeloid) and accelerated atherosclerotic cardiovascular disease. This article discusses a multidisciplinary clinical approach to the management of patients with clonal hematopoiesis. Key areas of research needed to establish evidence-based clinical care guidelines and intervention strategies for individuals with clonal hematopoiesis are discussed.",
keywords = "Clonal cytopenias of uncertain significance, Clonal hematopoiesis, Clonal hematopoiesis of indeterminate significance",
author = "Bolton, {Kelly L.} and Ahmet Zehir and Ptashkin, {Ryan N.} and Minal Patel and Dipti Gupta and Robert Sidlow and Elli Papaemmanuil and Berger, {Michael F.} and Levine, {Ross L.}",
note = "Funding Information: A. Zehir has received honoraria from Illumina. M.F. Berger has consulted and served on the advisory board for Roche and has received research support from Illumina . R. Levine is on the supervisory board of Qiagen. He is a scientific advisor to Loxo, Imago, C4 Therapeutics, and Isoplexis, which includes equity interest. He receives research support from and has consulted for Celgene and Roche . He has consulted for Lilly, Janssen, Astellas, Morphosys, and Novartis. He has received honoraria from Roche, Lilly, Amgen, and Gilead. Funding Information: A. Zehir has received honoraria from Illumina. M.F. Berger has consulted and served on the advisory board for Roche and has received research support from Illumina. R. Levine is on the supervisory board of Qiagen. He is a scientific advisor to Loxo, Imago, C4 Therapeutics, and Isoplexis, which includes equity interest. He receives research support from and has consulted for Celgene and Roche. He has consulted for Lilly, Janssen, Astellas, Morphosys, and Novartis. He has received honoraria from Roche, Lilly, Amgen, and Gilead. Publisher Copyright: {\textcopyright} 2019 Elsevier Inc.",
year = "2020",
month = apr,
doi = "10.1016/j.hoc.2019.11.006",
language = "English",
volume = "34",
pages = "357--367",
journal = "Hematology/Oncology Clinics of North America",
issn = "0889-8588",
number = "2",
}